【24h】

Management of the central compartment in differentiated thyroid carcinoma

机译:分化甲状腺癌中央隔室的管理

获取原文
获取原文并翻译 | 示例
           

摘要

Management of differentiated thyroid carcinoma (DTC) is gradually evolving with considerations of de-escalation of treatment and/or active surveillance in a significant proportion of patients on the basis of an improved understanding of the long-term disease and functional outcomes from both surgical and non-surgical approaches. This is fueled by improved risk stratification using clinicopathologic prognostic factors as determined through high resolution ultrasound and fine needle aspiration cytology. This paper discusses general recommendations for preoperative decision-making in the management of the central compartment in DTC with particular reference to micropapillary thyroid carcinoma and encapsulated follicular variant papillary thyroid carcinoma. Given the multitude of specific factors that must be considered for each patient, therapeutic decisions should occur in a multidisciplinary setting weighing the risks of treatment morbidity against the risks of disease progression or recurrence. Recurrent/persistent disease merits special attention with regard to pre-operative planning and surgical risk, and should be managed by high-volume thyroid surgeons.
机译:通过在大部分患者的脱升升级和/或积极监测的基础上,逐渐发展,逐渐发展,逐渐发展,并在大部分患者的基础上提高了对手术和外科手术的长期疾病和功能结果的影响非手术方法。这通过通过高分辨率超声和细针穿刺细胞学确定的临床病理学预后因素改善风险分层来推动。本文讨论了术前决策在DTC中央隔室管理中的一般性建议,特别是对微小足体甲状腺癌和包封的滤泡变异乳头状甲状腺癌。鉴于每位患者必须考虑的多种特定因素,治疗决策应在多学科设置中,称重治疗发病率的风险,免受疾病进展或复发的风险。反复性/持续性疾病在术前计划和手术风险方面的特别关注值得特别关注,并应由大容量甲状腺外科医生进行管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号